Showing 2271-2280 of 5554 results for "".
- Can Softening Stem Cells Coax Hair Growth in Aging Hair? Maybehttps://practicaldermatology.com/news/can-softening-stem-cells-coax-hair-growth-in-aging-hair/2461761/Hair follicle stem cells get stiff with age, making it harder for them to grow hair, but if the hair follicle’s stem cells are softened, they are more likely to produce hair, new research suggests. In a study in mice
- Survey Highlights Room for Improvement in AK Awarenesshttps://practicaldermatology.com/news/survey-highlights-room-for-improvement-in-ak-awareness/2461746/As many as 85% of people are unaware of actinic keratosis (AK), according to a new survey from Almirall. The survey of more than 2,500 participants over the age or 35 aimed to understand the level of knowledge about AK and skin health habits within the general population of Spain, Germa
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <
- More Phase 3 Data: Dermavant’s VTAMA Hits Primary and Secondary Endpoints for Kids and Adults with ADhttps://practicaldermatology.com/news/phase-3-data-dermavants-vtama-hits-primary-and-secondary-endpoints-for-kids-and-adults-with-ad/2461720/Dermavant Sciences’ VTAMA performed well in in adults and kids with atopic dermatitis, according to topline results from ADORING 1, the company’s second atopic dermatitis (AD) Phase 3 trial. VTAMA is a novel, aryl hydrocarbon receptor agonist, in development a
- LifeNet Health Acquires Bioventus's Wound Care Divisionhttps://practicaldermatology.com/news/lifenet-health-acquires-bioventuss-wound-care-division/2461711/LifeNet Health announced the expantion of its portfolio with the acquisition of Bioventus' wound care division. Financial terms of the acqusition were not disclosed. "Non-healing wounds are a modern health care crisis," LifeNet Health President an
- Stony Brook University Hospital and The Mollie Biggane Melanoma Foundation Promote Skin Cancer Prevention Through New Inpatient Initiativehttps://practicaldermatology.com/news/stony-brook-university-hospital-and-the-mollie-biggane-melanoma-foundation-promote-skin-cancer-prevention-through-new-inpatient-initiative/2461709/Stony Brook University Hospital (SBUH) and the Mollie Biggane Melanoma Foundation announce a collaboration to provide Stony Brook patients with skin cancer education through their inpatient Electronic Medical Records program, according to a news release. Historicall
- News You Can Use: MIPS Hardship Exception Available Nowhttps://practicaldermatology.com/news/news-you-can-use-mips-hardship-exception-available-now/2461702/Physicians may now apply for an Extreme and Uncontrollable Circumstances hardship exception to avoid an up to 9% penalty in the Merit-based Incentive Payment System (MIPS) thanks to advocacy from the American Medical Association and organized medicine about the ongoing impacts of the COVID-19 pub
- Dr. Suneel Chilukuri Named Hydrinity Accelerated Skin Science’s Chief Medical Advisorhttps://practicaldermatology.com/news/dr-suneel-chilukuri-named-hydrinity-accelerated-skin-sciences-chief-medical-advisor/2461692/Suneel Chilukuri, MD, is Hydrinity Accelerated Skin Science’s new Chief Medical Advisor. In this role, Dr. Chilukuri will chair the Hydrinity Accelerated Skin Science Medical Advisory Board. He will aid product development as well as develop and oversee all clinica